June 14, 2017 09:15 AM EDT
R&D

Aldeyra slides as lead drug flunks a pri­ma­ry end­point in PhI­Ib

John Carroll

Editor & Founder

First things first.

Aldeyra’s Phase IIb study for its lead eye drug ADX-102 failed the pri­ma­ry end­point in treat­ing al­ler­gic con­junc­tivi­tis. And if you …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

‭ Regulatory Lead / Head of Regulatory‬

Autonomy Bio Inc.

San Francisco, CA 94107, USA

TRENDING NOW

Phar­ma's wins and loss­es in Trump's sprawl­ing ex­ec­u­tive or­der on drug prices

Sarep­ta los­es CMO to RNA edit­ing up­start; An­oth­er wave of per­son­nel moves at Dyne

US drugs re­ly heav­i­ly on in­gre­di­ents made over­seas, new re­port shows

Biotech seed rounds sink to low­est lev­el in years as in­dus­try slump drags on

Sanofi to pay $125M up­front for two im­munol­o­gy drugs from lit­tle-known biotech

sponsored

New York-based part­ner­ship sets the stan­dard for ex­pand­ing clin­i­cal tri­al ac­cess for un­der­served and di­verse ...

A service from the Financial Times